Crédit Agricole Valuation

Is ACA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ACA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ACA (€13.05) is trading below our estimate of fair value (€34.59)

Significantly Below Fair Value: ACA is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACA?

Key metric: As ACA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ACA. This is calculated by dividing ACA's market cap by their current earnings.
What is ACA's PE Ratio?
PE Ratio6.6x
Earnings€6.04b
Market Cap€39.67b

Price to Earnings Ratio vs Peers

How does ACA's PE Ratio compare to its peers?

The above table shows the PE ratio for ACA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average8.8x
BNP BNP Paribas
6.2x7.3%€64.2b
GLE Société Générale Société anonyme
7.3x15.0%€20.8b
MLCFM CFM Indosuez Wealth Management
10.8xn/a€659.0m
BBRI Bank Rakyat Indonesia (Persero)
10.8x9.2%Rp662.9t
ACA Crédit Agricole
6.6x3.7%€39.7b

Price-To-Earnings vs Peers: ACA is good value based on its Price-To-Earnings Ratio (6.6x) compared to the peer average (8.8x).


Price to Earnings Ratio vs Industry

How does ACA's PE Ratio compare vs other companies in the European Banks Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ACA 6.6xIndustry Avg. 7.4xNo. of Companies46PE0612182430+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ACA is good value based on its Price-To-Earnings Ratio (6.6x) compared to the European Banks industry average (7.4x).


Price to Earnings Ratio vs Fair Ratio

What is ACA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio6.6x
Fair PE Ratio7.7x

Price-To-Earnings vs Fair Ratio: ACA is good value based on its Price-To-Earnings Ratio (6.6x) compared to the estimated Fair Price-To-Earnings Ratio (7.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ACA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€13.05
€16.56
+26.9%
12.1%€23.40€14.00n/a19
Nov ’25€14.13
€16.64
+17.8%
12.1%€23.40€14.00n/a19
Oct ’25€13.67
€16.29
+19.2%
12.6%€21.60€11.00n/a20
Sep ’25€14.16
€16.17
+14.2%
12.3%€21.60€11.00n/a20
Aug ’25€13.97
€16.02
+14.7%
12.6%€21.60€10.75n/a20
Jul ’25€13.10
€15.79
+20.5%
13.9%€21.60€10.50n/a20
Jun ’25€14.93
€15.43
+3.4%
11.9%€18.40€10.50n/a20
May ’25€14.55
€14.40
-1.0%
11.4%€17.30€10.50n/a20
Apr ’25€13.82
€14.29
+3.4%
12.2%€17.30€10.50n/a20
Mar ’25€12.60
€14.08
+11.7%
11.5%€17.30€10.50n/a20
Feb ’25€12.94
€14.38
+11.2%
9.3%€17.30€12.20n/a20
Jan ’25€12.85
€13.91
+8.2%
9.3%€17.30€12.00n/a20
Dec ’24€12.07
€13.62
+12.9%
9.5%€17.30€12.00n/a20
Nov ’24€11.42
€13.37
+17.1%
9.8%€17.30€11.50€14.1319
Oct ’24€11.69
€13.36
+14.2%
10.0%€17.30€11.50€13.6719
Sep ’24€11.65
€13.43
+15.3%
9.4%€17.30€11.70€14.1620
Aug ’24€11.16
€12.96
+16.1%
10.9%€17.30€11.30€13.9720
Jul ’24€10.87
€12.98
+19.4%
11.1%€17.30€11.30€13.1019
Jun ’24€10.69
€12.87
+20.4%
11.6%€17.30€11.00€14.9318
May ’24€11.08
€12.61
+13.8%
12.2%€17.30€10.50€14.5518
Apr ’24€10.40
€12.16
+16.9%
18.1%€17.30€5.55€13.8219
Mar ’24€11.39
€12.03
+5.7%
18.8%€17.30€5.55€12.6019
Feb ’24€11.07
€11.44
+3.3%
19.6%€17.30€5.55€12.9419
Jan ’24€9.83
€11.05
+12.4%
16.6%€14.80€5.55€12.8518
Dec ’23€9.50
€11.00
+15.8%
16.6%€14.80€5.55€12.0718
Nov ’23€9.30
€11.60
+24.7%
17.4%€15.00€5.55€11.4220

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies